For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | |||
|---|---|---|---|---|
| Accounting and audit fees | 145,579 | |||
| Research and development | 273,229 | |||
| Legal fees | 121,868 | |||
| Consulting fees | 73,243 | |||
| Salaries and wages | 340,030 | |||
| General and administrative - other | 159,915 | |||
| Total operating expenses | 1,113,864 | |||
| Loss from operations | -1,113,864 | |||
| Interest expenses/amortization of discount | 34,337 | |||
| Change in fair value of derivative liabilities | 203,354 | |||
| Foreign currency exchange differences | 6,677 | |||
| Total other income (expense) | 244,368 | |||
| Loss before income taxes | -869,496 | |||
| Net loss | -869,496 | |||
| Unrealized foreign currency translation (loss) gain | 37,072 | |||
| Comprehensive loss | -832,424 | |||
| Basic EPS | -0.47 | |||
| Diluted EPS | -0.47 | |||
| Basic Average Shares | 1,849,389 | |||
| Diluted Average Shares | 1,849,389 | |||
Protagenic Therapeutics, Inc. new (PTIX)
Protagenic Therapeutics, Inc. new (PTIX)